Vical’s proprietary core technology is based on plasmid DNA, or pDNA, closed loops of DNA that encode any protein of interest. When injected into tissues such as skeletal muscle or the skin, cells take up pDNA and produce the encoded protein, allowing for pDNA to be used as the basis for a broad range of biopharmaceutical products, including infectious disease vaccines.

Vical’s proprietary core technology is based on plasmid DNA, or pDNA, closed loops of DNA that encode any protein of interest. When injected into tissues such as skeletal muscle or the skin, cells take up pDNA and produce the encoded protein, allowing for pDNA to be used as the basis for a broad range of biopharmaceutical products, including infectious disease vaccines. Photo by Graphic courtesy of Vical

VICAL INC.

CEO: Vijay Samant.

Revenue: $8.7 million in 2010;

$12.7 million in 2009.

Net loss: $30.4 million in 2010; $28.6 million in 2009.

No. of local employees: 115.

Headquarters: Sorrento Valley.

Year founded: 1987.

Stock symbol and exchange: VICL on Nasdaq.

Company description: A biotechnology company that has patented technologies and methods for introducing DNA into the body for vaccines and cancer fighting.

With the award of a third patent for its advances in developing a vaccine for the herpes simplex virus, Vical Inc...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99